People
Gilead Sciences announces changes in executive positions
10 December 2018 -

Biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Monday that its board of directors elected Daniel O'Day as its chairman and chief executive officer, effective 1 March 2019.

Additionally, the company's board has named Gregg Alton as its interim chief executive officer for the period 1 January 2019 until O'Day's start date as of 1 March 2019.

More recently, Alton has held a number of executive positions at Gilead over the past 20 years, including general counsel and chief patient officer.

Currently, O'Day serves as chief executive officer of Roche Pharmaceuticals since 2012 as well as a member of the corporate executive committee of F. Hoffmann La Roche AG and Shanghai Roche Pharmaceuticals Ltd Roche (China).

Since joining Roche Pharmaceuticals in 1987, O'Day previously held leadership roles in Global Marketing and Lifecycle Management in Switzerland, head of Corporate Planning for Roche Pharmaceuticals in Japan, general manager in Denmark, president of Roche Molecular Diagnostics in California as well as lead the Diagnostics Division at Roche headquarters. Additionally, he has served as a member of the board of the European Federation of Pharmaceutical Industries and Associations.

In conjunction, the chairman John C. Martin, PhD will resign from the company's board of directors on 1 March 2019, O'Day's first day of employment. Concurrently, John F. Milligan, PhD, will step down as its president, chief executive officer as well as a member of the board at the end of 2018.

Login
Username:

Password: